Abrocitinib efficacy and safety in moderate-to-severe atopic dermatitis by race, ethnicity, and Fitzpatrick skin type

By sjmartinez • November 12, 2023

Alexis AF, Silverberg JI, Rice ZP, Armstrong AW, Desai SR, Fonacier L, Kabashima K, Biswas P, Cella RR, Chan GL, Levenberg M. Abrocitinib efficacy and safety in moderate-to-severe atopic dermatitis by race, ethnicity, and Fitzpatrick skin type. Ann Allergy Asthma Immunol. 2023 Nov 8:S1081-1206(23)01394-7. doi: 10.1016/j.anai.2023.11.002. Epub ahead of print. PMID: 37949351.

Tags: abrocitinib, atopic eczema, Clinical Trial, Dermatology, Ethnicity, Publications, Race

Patient-Reported Outcomes by Baseline Body Surface Area Involvement Among Individuals Initiating Biologic Therapy: Results from the CorEvitas Psoriasis Registry

Armstrong AW, Feldman SR, Fitzgerald T, Alkousakis T, Sima A, Li A, Kang HJ, Main SI, Khattri S, Stein Gold L. Patient-Reported Outcomes by Baseline[...]

Biologic Mechanisms Underlying the Heterogeneous Response to Tight Glycemic Control among Differentially Inflamed Patients in the HALF-PINT Trial

Zinter MS, Taylor CS, Markovic D, Pellegrini M, Wong K, Balliu B, Gala KP, Asaro LA, Nadkarni VM, McQuillen PS, Vangala SS, Sinha P, Matthay[...]

Cutaneous manifestation of metastatic papillary thyroid carcinoma

Peng D, Dong E, Martinez D, Kang Y, Wong D, Holland V. Cutaneous manifestation of metastatic papillary thyroid carcinoma. JAAD Case Rep. 2025 Apr 11;60:129-131.[...]